Affiliation:
1. DEPARTMENT OF NEUROLOGY, POZNAN UNIVERSITY OF MEDICAL SCIENCES, POZNAN, POLAND
2. LABORATORY OF FLOW CYTOMETRY AND VASCULAR BIOLOGY, DEPARTMENT OF NEUROLOGY, POZNAN UNIVERSITY OF MEDICAL SCIENCES, POZNAN, POLAND
Abstract
Introduction: Elevated concentrations of platelet-derived microvesicles are found in cerebrovascular diseases. The impact of acetylsalicylic acid on these microvesicles remains inconsistent, despite its well-established effect on platelet aggregation. High residual platelet aggregation is defined as high on-treatment platelet reactivity, while “treatment failure” is the occurrence of vascular events despite antiplatelet treatment.
The aim of this study was to determine whether the antiaggregatory effect of acetylsalicylic acid correlates with platelet-derived microvesicles in convalescent ischaemic stroke patients and cardiovascular risk factor controls as well as to evaluate the association between high on-treatment platelet reactivity and recurrent vascular events with the studied platelet-derived microvesicle parameters.
Materials and methods: The study groups consisted of 76 convalescent stroke patients and 74 controls. Total platelet-derived microvesicles, annexino-positive microvesicles
number, and platelet-derived microvesicles with surface expression of proinflammatory (CD40L, CD62P, CD31) and procoagulant (PS, GPIIb/IIIa) markers were characterized
and quantified using flow cytometry. Cyclooxygenase-1-specific platelet responsiveness, with whole blood impedance platelet aggregation under arachidonic acid stimulation and the serum concentration of thromboxane B2, were evaluated.
Results: Neither acetylsalicylic acid intake nor modification of its daily dose caused statistically significant differences in the studied microvesicle parameters. Additionally, no statistically significant differences in the studied microvesicle parameters were revealed between high on-treatment platelet reactivity and non-high on-treatment platelet reactivity subjects in either study subgroup. However, elevated concentrations of PAC-1+/CD61+, CD62P+/CD61+ and CD31+/CD61+ microvesicles were found in stroke patients with treatment failure, defined in this study as a recurrent vascular events in a one-year follow-up period.
Conclusions: This study revealed no relationship between circulating microvesicle number and platelet aggregation. The procoagulant and proinflammatory phenotype of
circulating platelet-derived microvesicles might contribute to acetylsalicylic acid treatment failure.
Reference35 articles.
1. 1. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Reviews 2007;21(3):157–71.
2. 2. Lee YJ, Jy W, Horstman LL et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thrombosis Research 1993;72(4):295–304.
3. 3. Shirafuji T, Hamaguchi H, Kanda F. Measurement of platelet-derived microparticle level in the chronic phase of cerebral infarction using an enzyme-linked immunosorbent assay. The Kobe Journal of Medical Sciences 2008;54(1):E55–61.
4. 4. Cherian P, Graeme JH, John WE et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003;34(9):2132–7.
5. 5. Lukasik M, Rozalski M, Luzak B et al. Enhanced platelet-derived microparticle formation is associated with carotid atherosclerosis in convalescent stroke patients. Platelets 2013;24(1):63–70.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献